Brian Guan-Chyun Liu Acquires 1,515,151 Shares of CG Oncology (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Brian Guan-Chyun Liu bought 1,515,151 shares of CG Oncology stock in a transaction dated Thursday, September 11th. The stock was acquired at an average price of $33.00 per share, with a total value of $49,999,983.00. Following the acquisition, the director directly owned 1,515,151 shares of the company’s stock, valued at approximately $49,999,983. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

CG Oncology Stock Performance

Shares of NASDAQ:CGON traded up $0.85 during midday trading on Monday, hitting $34.19. 341,313 shares of the stock were exchanged, compared to its average volume of 984,831. CG Oncology, Inc. has a 52-week low of $14.80 and a 52-week high of $40.47. The business’s fifty day simple moving average is $27.20 and its two-hundred day simple moving average is $25.55. The company has a market capitalization of $2.61 billion, a PE ratio of -19.33 and a beta of 0.87.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%. As a group, equities analysts anticipate that CG Oncology, Inc. will post -1.31 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CGON shares. The Goldman Sachs Group raised CG Oncology to a “strong-buy” rating and set a $40.00 target price on the stock in a research report on Thursday, July 10th. Morgan Stanley lifted their target price on CG Oncology from $52.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 17th. Piper Sandler started coverage on CG Oncology in a research report on Monday, August 18th. They set an “overweight” rating and a $55.00 target price on the stock. Royal Bank Of Canada decreased their target price on CG Oncology from $68.00 to $53.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 16th. Finally, HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of CG Oncology in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, CG Oncology presently has an average rating of “Moderate Buy” and an average target price of $53.91.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Swiss National Bank grew its holdings in shares of CG Oncology by 1.9% during the first quarter. Swiss National Bank now owns 81,100 shares of the company’s stock worth $1,986,000 after buying an additional 1,500 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of CG Oncology by 53.5% in the 4th quarter. Deutsche Bank AG now owns 38,978 shares of the company’s stock valued at $1,118,000 after acquiring an additional 13,589 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of CG Oncology by 8.2% in the 1st quarter. Rhumbline Advisers now owns 74,689 shares of the company’s stock valued at $1,829,000 after acquiring an additional 5,673 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of CG Oncology by 1,051.0% in the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company’s stock valued at $56,000 after acquiring an additional 2,102 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of CG Oncology by 3.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,080 shares of the company’s stock valued at $862,000 after acquiring an additional 1,026 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.